Program
CS5007
A development code.
Its studies are led by CStone Pharmaceuticals.
Furthest: phase 1, since May 28, 20261 company-led study, 1 open or runningNext primary completion: Jan 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CStone Pharmaceuticals | 11 open or running | phase 1since May 28, 2026 | May 28, 2026 | Jan 2028phase 1 · NCT07622524 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 28, 2026First study: phase 1 study in Advanced Solid TumorsFirst studyNCT07622524 · 310 planned · Australia, China
Ahead
- Jan 2028Primary completion: phase 1 study in Advanced Solid TumorsNCT07622524
TargetBeta
“A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti Tumor Activities of CS5007, a Novel EGFR and HER3 Bispecific Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors”study text, by rule · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418rule | avenzo-therapeutics-inc | phase 2 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07622524Advanced Solid Tumors · Australia, China | 1 | Recruiting | Jan 2028 | 310 |
How it is read
Names in the registry
- “CS5007”, 1 entry
Codes read as this program: CS5007.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.